UBS Group’s Titan Pharmaceuticals TTNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-480
| Closed | -$2.3K | – | 11169 |
|
|
2025
Q3 | $2.3K | Sell |
480
-2,947
| -86% | -$13K | ﹤0.01% | 9190 |
|
|
2025
Q2 | $14.4K | Buy |
3,427
+833
| +32% | +$3.53K | ﹤0.01% | 8653 |
|
|
2025
Q1 | $9.16K | Sell |
2,594
-73
| -3% | -$263 | ﹤0.01% | 8707 |
|
|
2024
Q4 | $8.69K | Sell |
2,667
-2,106
| -44% | -$8.57K | ﹤0.01% | 8390 |
|
|
2024
Q3 | $25.2K | Buy |
4,773
+4,772
| +477,200% | +$27.4K | ﹤0.01% | 7240 |
|
|
2024
Q2 | $6 | Hold |
1
| – | – | ﹤0.01% | 9390 |
|
|
2024
Q1 | $7 | Buy |
+1
| New | +$7 | ﹤0.01% | 9128 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 9211 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 9352 |
|
|
2023
Q2 | – | Sell |
-76
| Closed | -$1.27K | – | 9669 |
|
|
2023
Q1 | $1.27K | Buy |
76
+68
| +850% | +$1.22K | ﹤0.01% | 8771 |
|
|
2022
Q4 | $129 | Sell |
8
-551
| -99% | -$10.4K | ﹤0.01% | 10369 |
|
|
2022
Q3 | $12K | Sell |
559
-788
| -59% | -$20.3K | ﹤0.01% | 8187 |
|
|
2022
Q2 | $15K | Buy |
1,347
+991
| +278% | +$12.4K | ﹤0.01% | 7318 |
|
|
2022
Q1 | $7K | Buy |
356
+166
| +87% | +$3.45K | ﹤0.01% | 8845 |
|
|
2021
Q4 | $4K | Sell |
190
-165
| -46% | -$4.97K | ﹤0.01% | 9552 |
|
|
2021
Q3 | $13K | Sell |
355
-59
| -14% | -$2.58K | ﹤0.01% | 7686 |
|
|
2021
Q2 | $22K | Sell |
414
-759
| -65% | -$38K | ﹤0.01% | 7240 |
|
|
2021
Q1 | $70K | Buy |
1,173
+870
| +287% | +$57.6K | ﹤0.01% | 6240 |
|
|
2020
Q4 | $20K | Buy |
303
+297
| +4,950% | +$23.5K | ﹤0.01% | 6952 |
|
|
2020
Q3 | $1K | Sell |
6
-188
| -97% | -$29K | ﹤0.01% | 7840 |
|
|
2020
Q2 | $36K | Buy |
194
+68
| +54% | +$11.7K | ﹤0.01% | 6143 |
|
|
2020
Q1 | $18K | Buy |
126
+55
| +77% | +$8.59K | ﹤0.01% | 6558 |
|
|
2019
Q4 | $8K | Buy |
71
+69
| +3,450% | +$8.31K | ﹤0.01% | 7402 |
|
|
2019
Q3 | $0 | Sell |
2
-1
| -33% | -$451 | ﹤0.01% | 8260 |
|
|
2019
Q2 | $2K | Sell |
3
-10
| -77% | -$9.14K | ﹤0.01% | 7636 |
|
|
2019
Q1 | $14K | Buy |
13
+8
| +160% | +$7.77K | ﹤0.01% | 6599 |
|
|
2018
Q4 | $4K | Buy |
5
+4
| +400% | +$4.49K | ﹤0.01% | 7643 |
|
|
2018
Q3 | $1K | Buy |
+1
| New | +$2.72K | ﹤0.01% | 7855 |
|
|
2018
Q2 | – | Sell |
-1
| Closed | -$3.35K | – | 8251 |
|
|
2018
Q1 | $2K | Buy |
+1
| New | +$4.18K | ﹤0.01% | 7555 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | -$6.22K | – | 8104 |
|
|
2017
Q3 | $8K | Hold |
1
| – | – | ﹤0.01% | 7007 |
|
|
2017
Q2 | $4K | Buy |
+1
| New | +$9.3K | ﹤0.01% | 7220 |
|
|
2017
Q1 | – | Sell |
-1
| Closed | -$14.1K | – | 7206 |
|
|
2016
Q4 | $13K | Hold |
1
| – | – | ﹤0.01% | 6772 |
|
|
2016
Q3 | $11K | Buy |
+1
| New | +$19.4K | ﹤0.01% | 6732 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7344 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 7331 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 7793 |
|
Other funds holding TTNP
CA
GWSA
CSC
DJSG
UBS Group's TTNP Position: Q4 2025 in Review
UBS Group sold out of Titan Pharmaceuticals (TTNP) in Q4 2025, closing a stake of 480 shares — an estimated $2.3K sold.
UBS Group first reported a position in TTNP in Q3 2016 and held it in 31 quarters. The position peaked at $70K in Q1 2021. 4 funds tracked by Wall St. Rank hold TTNP as of Q4 2025.
- UBS Group reported no remaining Titan Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 480 Titan Pharmaceuticals shares in Q4 2025, an estimated $2.3K.
- UBS Group first reported a position in Titan Pharmaceuticals in Q3 2016 and held it in 31 quarters.
- UBS Group's Titan Pharmaceuticals position peaked at $70K in Q1 2021.
- 4 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.